FDA Grants BridgeBio Oncology Therapeutics Fast Track Designation To BBO-11818
Benzinga Newsdesk 6 months ago
BiotechNewsFDAGeneral
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumorsUpdated Phase 1 clinical data are expected in the second half
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
Updated Phase 1 clinical data are expected in the second half of 2026